Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
about
The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms.Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycinRole of linezolid in the treatment of orthopedic infections.Incidence and Outcomes Associated With Infections Caused by Vancomycin-Resistant Enterococci in the United States: Systematic Literature Review and Meta-Analysis.Linezolid: effectiveness and safety for approved and off-label indications.The evaluation and treatment of complicated skin and skin structure infections.Multicenter study of high-dose daptomycin for treatment of enterococcal infectionsTargeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Linezolid for patients with neutropenia: are bacteriostatic agents appropriate?Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Vancomycin-resistant enterococcal meningitis in an autologous stem cell transplant recipient cured with linezolid.Current and prospective treatments for multidrug-resistant gram-positive infections.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Early optimization of antimicrobial therapy improves clinical outcomes of patients administered agents targeting methicillin-resistant Staphylococcus aureus.Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
P2860
Q35873712-60FE3548-1FD8-4870-BBB3-281D0C029514Q35959558-EEFC0D3F-23F6-40CD-B7D8-7C53B608B3A5Q36162348-AB21F0E4-AB56-4DAB-AC25-2CA4F09E77E5Q36186175-88C5B868-699D-47C6-8D1F-FE94D064F47CQ36967288-686ED686-E3C5-4213-AD04-B9AC1AC8D709Q37111836-08B49BA1-05AF-454C-B057-64FB8BAF9DFAQ37124177-B0157397-618A-4FA7-A954-0E616EBB7297Q37377897-7A8244D0-EDD6-481D-9800-2AEEA13D28ECQ37463209-2F17E8EF-500F-4BA3-9372-39A62B81435FQ37785546-800D381E-589D-4182-9CFA-D1E019DFB352Q38061694-96C14CDA-35A7-47B0-8E59-228F6AC03A8BQ38123255-00609328-1E67-4B7D-90B7-2696B4E8C364Q38263421-9B749618-8F90-43E2-AD8A-1645BEC329A6Q38347869-A500F6D4-8451-4B35-9194-4BB26CA63F4FQ38672248-96473FF5-A348-42EC-8CD0-94A904C86DA1Q43044219-2932B575-DDE2-48A1-AE38-177CA6C924EB
P2860
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Prospective, randomized study ...... terococcus faecium infections.
@ast
Prospective, randomized study ...... terococcus faecium infections.
@en
type
label
Prospective, randomized study ...... terococcus faecium infections.
@ast
Prospective, randomized study ...... terococcus faecium infections.
@en
prefLabel
Prospective, randomized study ...... terococcus faecium infections.
@ast
Prospective, randomized study ...... terococcus faecium infections.
@en
P2093
P356
P1476
Prospective, randomized study ...... terococcus faecium infections.
@en
P2093
Carmen Escalante
Claude Afif
Hend Hanna
Issam Raad
Kenneth Rolston
Ray Hachem
P304
P356
10.1093/JAC/DKH144
P407
P577
2004-03-03T00:00:00Z